Sylvester, Richard J. and Rodriguez, Oscar and Hernandez, Virginia and Turturica, Diana and Bauerova, Lenka and Bruins, Harman Max and Bruendl, Johannes and van der Kwast, Theo H. and Brisuda, Antonin and Rubio-Briones, Jose and Seles, Maximilian and Hentschel, Anouk E. and Kusuma, Venkata R. M. and Huebner, Nicolai and Cotte, Juliette and Mertens, Laura S. and Volanis, Dimitrios and Cussenot, Olivier and Henriquez, Jose D. Subiela and de la Pena, Enrique and Pisano, Francesca and Pesl, Michael and van der Heijden, Antoine G. and Herdegen, Sonja and Zlotta, Alexandre R. and Hacek, Jaromir and Calatrava, Ana and Mannweiler, Sebastian and Bosschieter, Judith and Ashabere, David and Haitel, Andrea and Cote, Jean-Francois and El Sheikh, Soha and Lunelli, Luca and Algaba, Ferran and Alemany, Isabel and Soria, Francesco and Runneboom, Willemien and Breyer, Johannes and Nieuwenhuijzen, Jakko A. and Llorente, Carlos and Molinaro, Luca and Hulsbergen-van de Kaa, Christina A. and Evert, Matthias and Kiemeney, Lambertus A. L. M. and N'Dow, James and Plass, Karin and Capoun, Otakar and Soukup, Viktor and Dominguez-Escrig, Jose L. and Cohen, Daniel and Palou, Joan and Gontero, Paolo and Burger, Maximilian and Zigeuner, Richard and Mostafid, Amir Hugh and Shariat, Shahrokh F. and Roupret, Morgan and Comperat, Eva M. and Babjuk, Marko and van Rhijn, Bas W. G. (2021) European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. EUROPEAN UROLOGY, 79 (4). pp. 480-488. ISSN 0302-2838, 1873-7560
Full text not available from this repository. (Request a copy)Abstract
Background: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. Objective: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression. Design, setting, and participants: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel. Intervention: Patients underwent TURBT followed by intravesical instillations at the physician's discretion. Outcome measurements and statistical analysis: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves. Results and limitations: A total of 3401 patients treated with TURBT + intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review. Conclusions: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for which urologists should be prompt to assess and adapt their therapeutic strategy when necessary. Patient summary: The newly updated European Association of Urology prognostic factor risk groups for non-muscle-invasive bladder cancer provide an improved basis for recommending a patient's treatment and follow-up schedule. (C) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BACILLUS-CALMETTE-GUERIN; CARCINOMA IN-SITU; PREDICTING RECURRENCE; PROGRESSION; TA; MULTICENTER; SURVIVAL; OUTCOMES; IMPACT; TUMORS; Grade; Guidelines; Non-muscle-invasive bladder cancer; Prognostic factors; Progression; Risk groups; WHO 1973 2004/2016 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Sep 2022 08:56 |
| Last Modified: | 27 Sep 2022 08:56 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48039 |
Actions (login required)
 |
View Item |
